An observational study in Comorbidities and HIV/AIDS, sponsored by Asociacion para el Estudio de las Enfermedades Infecciosas. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.
Sponsored by Asociacion para el Estudio de las Enfermedades Infecciosas · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Acquired Immunodeficiency Syndrome with a site in Spain — 6 open to participants now, 13 under way, 3 of them phase 3. Acquired Immunodeficiency Syndrome · Spain.
Among the 96 studies in Acquired Immunodeficiency Syndrome with a site in Spain, this one is the 8th largest by enrollment of the 17 observational ones that give a count, is the only one that started in 2017, is one of 17 observational ones, and was the 67th registered.
3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →6 of the 96 studies in Acquired Immunodeficiency Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 6 more countries
Ages 18+
Casper Rokx · Sites in Spain, Belgium, France and 7 more countries
Ages 18+ · Healthy volunteers
Danone Specialized Nutrition · Sites in Spain
Ages 18+
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 14–65 · Healthy volunteers
Rigshospitalet, Denmark · Sites in Spain, Argentina, Austria and 33 more countries
Ages 16+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 39 · Phase 4 9
First in 1994; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 360 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 212 across the 79 interventional studies, 355 across the 17 observational. Of the 73 that completed or were terminated, 46 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 96 have an industry lead sponsor. The 10 most frequent:
Asociacion para el Estudio de las Enfermedades Infecciosas is the lead sponsor of 9 studies on the registry; none are open to participants now.
Asociacion para el Estudio de las Enfermedades Infecciosas has 1 study filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Acquired Immunodeficiency Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT06497504GlaxoSmithKlineStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 96 studies in Acquired Immunodeficiency Syndrome with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Retrospective cohort of virologically suppressed HIV-infected patients who received the combination of Raltegravir plus Darunavir boosted with cobicistat or ritonavir, as dual therapy, because or toxicity or intolerance to nucleoside analogues
This is a retrospective cohort study including those HIV-infected patients who received the combination of raltegravir plus darunavir boosted with cobicistat or ritonavir as dual therapy, due to the existence of toxicity or intolerance to nucleoside analogues, to evaluate:
Patients will included if they have received at least 1 dose of the dual therapy
HIV infected patients with virological suppression but toxicity or intolerance to analogues who switched to the combination of Raltegravir plus boosted Darunavir
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Outcome of patients will be collected from charts to evaluate primary and secondary objectives
Percentage of patients who maintained virological suppression on treatment at 48 weeks after using this dual therapy
The number of patients who remained with virological suppression during the study at 48 weeks (ITT-exposed, snapchot analysis)
Time frame: 48 weeks
Change in renal parameters at 48 weeks,for patients using dual therapy
Evaluation of renal parameters in patients changing to this dual therapy, considering the previous use of TDF or not.
Time frame: 48 weeks
Change in bone parameters (bone mineral density by Dual X-ray absorptiometry) during the study
Quantitative changes in bone mineral density (BMD) according to previous use of TDF and renal parameters
Time frame: 48 weeks
Change in cardiovascular risk (by using AHA score) for patients using dual therapy
Changes in lipid parameters will be assessed
Time frame: 48 weeks
Changes in inflammatory markers during the study, measured by the CD4/CD8 ratio
Those patients who received this dual therapy will be evaluated to determine changes in inflammatory biomarkers such as CD4/CD8 ratio
Time frame: 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2017 to primary completion in Jun 2018, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →
Asociacion para el Estudio de las Enfermedades Infecciosas